newsfilter
← Latest News
GlobeNewswire·

NeuroMetrix Announces Peer-Reviewed Publication of Phase 2 Clinical Trial Showing that Quell® Improves Painful Symptoms of Chemotherapy Induced Peripheral Neuropathy (CIPN)

WOBURN, Mass., Dec. 05, 2023 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (NASDAQ:NURO) noted publication of results from a NIH-funded clinical trial of Quell titled "Wireless transcutaneous electric nerve stimulation